Top

Published in:

01-12-2007 | Clinical Trial

CYP1B1 and predisposition to breast cancer in Poland

Authors: Joanna Matyjasik, Cezary Cybulski, Bartlomiej Masojć, Anna Jakubowska, Pablo Serrano-Fernandez, Bohdan Górski, Tadeusz Dębniak, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Elzbieta Złowocka, Steven Alexander Narod, Rodney Scott, Jan Lubinski

Published in: Breast Cancer Research and Treatment | Issue 3/2007

Abstract

Background

The CYP1B1 gene is a polymorphic member of the P450 gene family and is considered to be a candidate gene for cancers of various types.

Objective

We inquired whether four SNPs in the CYP1B1 gene, alone or in combination, might be associated with breast cancer risk in Poland.

Methods

We genotyped 2017 cases of breast cancer and 876 controls, for four SNPs in the CYP1B1 gene. Genotype and haplotype frequencies were compared in cases and controls.

Results

In combinations of the R48G, A119S and L432V SNPs, four of the eight CYP1B1 haplotypes were more common in controls than in cases and each of these appeared to have a significant protective effect. A large reduction in risk was observed for women who were homozygous for one of these four haplotypes (OR = 0.2; 95%; CI = 0.05–0.5; P = 0.001) compared to women who were homozygous for the most common haplotype. In contrast, women who were homozygous for the GTC haplotype were at increased risk (OR = 1.5; 95%; CI = 1.0–2.1; P = 0.03) compared to women with the most common haplotype.

Conclusions

The CYP1B1 gene appears to influence breast cancer susceptibility in Poland.

Hayes CL, Spink DC, Spink BC et al (1996) 17β-Estradiol hydroxylation catalysed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 93:9776–9781PubMedCrossRef

Spink DC, Eugster H, Lincoln II DW et al (1992) 17β-Estradiol hydroxylation catalysed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8, -tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 293:342–348PubMedCrossRef

Spink DC, Hayes CL, Young NR et al (1994) The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17β-estradiol 4-hydroxylase. J Steroid Biochem Mol Biol 51:251–258PubMedCrossRef

Han X, Liehr JG (1994) DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens:hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 15:997–1000PubMedCrossRef

Chakravarti D, Mailander PC, Li KM et al (2001) Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 20:7945–7953PubMedCrossRef

Service RF (1998) New role for estrogen in cancer. Science 279:1631–1633PubMedCrossRef

Jan ST, Devanesan PD, Stack DE et al (1998) Metabolic activation and formation of DNA adducts of hexestrol, a synthetic nonsteroidal carcinogenic estrogen. Chem Res Toxicol 11:412–419PubMedCrossRef

Watanabe J, Shimada T, Gillam EM et al (2000) Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetic 10:25–33CrossRef

Gotoh O, Tagashira Y, Lizuka T et al (1983) Structural characteristic of cytochrome P450; possible location of the heme-binding cysteine in determined amino acid sequence. J Biochem 93:807–817PubMed

10.

Hanna IH, Dawling S, Roodi N, et al (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60:3440–3444PubMed

11.

Shimada T, Hayes CL, Yamazaki H et al (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56:2979–2984PubMed

12.

Shimada T, Watanabe J, Kawajiri K et al (1999) Catalytic properties of polymorphic human cytochrome P4501B1 variants. Carcinogenesis 20:1607–1613PubMedCrossRef

13.

Rylander-Rudqvist T, Wedren S, Granath F et al (2003) Cytochrome P450 1B1 gene polymorphisms and post menopausal breast cancer risk. Carcinogenesis 24:1533–1539PubMedCrossRef

14.

Bailey LR, Roodi N, Dupont WD et al (1998) Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 58:5038–5041PubMed

15.

De Vivo I, Hankinson SE, Li L et al (2002) Association of CYP1B1 Polymorphisms and Breast Cancer Risk. Cancer Epidemiol Biomarkers Prev 11:489–492PubMed

16.

Aksan H, Chen Y, Whittemore AS et al (2004) A family –based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk. Breast Cancer Res Treat 85:121–131CrossRef

17.

Kocabas NA, Sardas S, Cholerton S et al (2002) Cytochrome P450 and catechol O-methyltransferase (COMT) genetic polymorphism and breast cancer susceptibility in a Turkish population. Arch Toxicol 76:643–649PubMedCrossRef

18.

Zheng W, Xie DW, Jin F et al (2000) Genetic Polymorphism of Cytochrome P450–1B1 and Risk of Breast Cancer. Cancer Epidemiol Biomarkers Prev 9:147–150PubMed

19.

Schaid DJ, Rowland CM, Tines DE et al (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434PubMedCrossRef

20.

Chang BL, Zheng SL, Isaacs SD et al (2003) Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. British Journal of Cancer 89:1524–1529PubMedCrossRef

21.

Cicek MS, Liu X, Carey G et al (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 14:2173–2177PubMedCrossRef

22.

Wen W, Cai Q, Shu XO et al (2005) Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the Shanghai breast cancer study and meta-analysis. Cancer Epidemiol Biomarkers Prev 14:329–35PubMedCrossRef

23.

Gallicchio L, Berndt SI, McSorley MA et al (2006) Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer 6:173PubMedCrossRef

Title: CYP1B1 and predisposition to breast cancer in Poland
Authors: Joanna Matyjasik
Cezary Cybulski
Bartlomiej Masojć
Anna Jakubowska
Pablo Serrano-Fernandez
Bohdan Górski
Tadeusz Dębniak
Tomasz Huzarski
Tomasz Byrski
Jacek Gronwald
Elzbieta Złowocka
Steven Alexander Narod
Rodney Scott
Jan Lubinski
Publication date: 01-12-2007
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9500-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2007

Ultrasound-guided core needle biopsy of the breast: does frozen section give an accurate diagnosis?

Endothelial progenitor cells in breast cancer patients

On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer

Study of time-course changes in annual recurrence rates for breast cancer: data analysis of 2,209 patients for 10 years post-surgery

Quantitative exploration of possible reasons for the recent improvement in breast cancer survival

Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement

Keynote webinar | Spotlight on antibody–drug conjugates in cancer